VYNE
NASDAQVYNE Therapeutics Inc.
Price$0.51-31.49 (-98.41%)
2026-04-212026-07-24
News · 26 weeks32+117%
2026-02-012026-07-26
Mix2590d
- SEC Filings12(48%)
- Insider9(36%)
- Dividends3(12%)
- Other1(4%)
Latest news
25 items- INSIDERCHIEF FINANCIAL OFFICER Zeronda Tyler covered exercise/tax liability with 22,516 shares, decreasing direct ownership by 23% to 74,918 units (SEC Form 4) (withholding obligation)4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
- INSIDERCHIEF SCIENTIFIC OFFICER Stuart Iain covered exercise/tax liability with 15,405 shares, decreasing direct ownership by 14% to 95,944 units (SEC Form 4) to cover taxes4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
- INSIDERPRESIDENT AND CEO Domzalski David covered exercise/tax liability with 79,391 shares, decreasing direct ownership by 19% to 347,174 units (SEC Form 4) (for tax liability)4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
- INSIDERCHIEF LEGAL OFFICER AND GC Harsch Mutya covered exercise/tax liability with 22,516 shares, decreasing direct ownership by 19% to 95,918 units (SEC Form 4) to satisfy withholding tax4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
- PRVYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow BioscienceNEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company") today announced that its previously announced special cash dividend (the "Cash Dividend"), declared in connection with the terms and conditions of the Agreement and Plan of Merger and Reorganization, entered into on December 17, 2025, as amended (the "Merger Agreement"), with Yarrow Bioscience, Inc. ("Yarrow") and Yellow Merger Sub Corp., was distributed, in cash, on July 23, 2026 to VYNE’s stockholders of record as of July 22, 2026 (the "Record Date"), subject to the Nasdaq due bill procedures described below, based on their holdings as of the Record Date and during the Due Bill Per
- SECVYNE Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - VYNE Therapeutics Inc. (0001566044) (Filer)
- PRVYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow BioscienceNEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company") today announced that its Board of Directors has approved a reverse stock split of VYNE’s common stock at a ratio of 1-for-50 in connection with the anticipated closing of the proposed merger (the "Merger") with Yarrow Bioscience, Inc. ("Yarrow"). The reverse stock split was previously approved by VYNE’s stockholders at VYNE’s special meeting in lieu of the annual meeting of stockholders held on July 16, 2026 (the "Special Meeting"). Following the Merger, the combined company’s common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Capital Market ("
- SECVYNE Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - VYNE Therapeutics Inc. (0001566044) (Filer)
- SECSEC Form 425 filed by VYNE Therapeutics Inc.425 - VYNE Therapeutics Inc. (0001566044) (Subject)
- SECVYNE Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - VYNE Therapeutics Inc. (0001566044) (Filer)
- SECSEC Form 425 filed by VYNE Therapeutics Inc.425 - VYNE Therapeutics Inc. (0001566044) (Subject)
- SECVYNE Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - VYNE Therapeutics Inc. (0001566044) (Filer)
- PRVYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow BioscienceNEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company") today announced that its Board of Directors has declared a special cash dividend (the "Cash Dividend") in connection with the previously announced merger (the "Merger") with Yarrow Bioscience, Inc. ("Yarrow") pursuant to the Agreement and Plan of Merger and Reorganization, dated December 17, 2025 (as amended, the "Merger Agreement"). The Cash Dividend, which VYNE estimates will be an aggregate of $16.5 million, or an estimated $0.38 per share, will be payable in cash to the stockholders and warrant holders of record as of July 22, 2026. The estimated cash dividend is based on VYNE’s g
- INSIDERCHIEF LEGAL OFFICER AND GC Harsch Mutya covered exercise/tax liability with 3,464 shares, decreasing direct ownership by 3% to 118,434 units (SEC Form 4) (for tax liability)4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
- INSIDERPRESIDENT AND CEO Domzalski David covered exercise/tax liability with 12,214 shares, decreasing direct ownership by 3% to 426,565 units (SEC Form 4) (tax liability)4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
- INSIDERCHIEF SCIENTIFIC OFFICER Stuart Iain covered exercise/tax liability with 2,370 shares, decreasing direct ownership by 2% to 111,349 units (SEC Form 4) (tax withholding)4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Zeronda Tyler covered exercise/tax liability with 3,464 shares, decreasing direct ownership by 3% to 97,434 units (SEC Form 4) to cover taxes4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
- SECSEC Form EFFECT filed by VYNE Therapeutics Inc.EFFECT - VYNE Therapeutics Inc. (0001566044) (Filer)
- SECSEC Form 424B3 filed by VYNE Therapeutics Inc.424B3 - VYNE Therapeutics Inc. (0001566044) (Filer)
- SECAmendment: SEC Form S-4/A filed by VYNE Therapeutics Inc.S-4/A - VYNE Therapeutics Inc. (0001566044) (Filer)
- INSIDERPRESIDENT AND CEO Domzalski David was granted 30,791 shares, increasing direct ownership by 8% to 438,779 units (SEC Form 4)4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
- SECVYNE Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - VYNE Therapeutics Inc. (0001566044) (Filer)
- SECSEC Form SCHEDULE 13G filed by VYNE Therapeutics Inc.SCHEDULE 13G - VYNE Therapeutics Inc. (0001566044) (Subject)
- SECSEC Form 10-Q filed by VYNE Therapeutics Inc.10-Q - VYNE Therapeutics Inc. (0001566044) (Filer)
- SECAmendment: SEC Form S-4/A filed by VYNE Therapeutics Inc.S-4/A - VYNE Therapeutics Inc. (0001566044) (Filer)
VYNE FAQ
7 questionsWhat does VYNE Therapeutics Inc. do?
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older; and ZILXI for the treatment of inflammation lesions of papulopustular rosacea in adults. It is also developing FCD105, a topical combination foam that has completed Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib...Where does VYNE stock trade?
VYNE Therapeutics Inc. (VYNE) is listed on NASDAQ.What sector and industry is VYNE in?
VYNE Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did VYNE Therapeutics Inc. go public?
VYNE Therapeutics Inc. (VYNE) completed its IPO in 2018.What are analysts saying about VYNE?
VYNE Therapeutics Inc. has had 3 recent analyst actions on file. The most recent action was from BTIG Research: Neutral on 2025-07-31. Recent price targets range from $700.00 to $800.00.What companies are similar to VYNE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare VYNE side-by-side with any of them on Quantisnow.How can I track VYNE on Quantisnow?
Quantisnow aggregates VYNE Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VYNE to receive live email and push alerts on every new disclosure.